EMORY UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1836-12-10

Employees: 10K

Market Cap: -

Website: http://www.emory.edu

Clinical Trials

Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment

Phase 2

Active, not recruiting

Conditions: Bladder Cancer

Interventions: Drug: Sugar pill
Drug: Genistein

First Posted Date: 2011-12-12

Last Posted Date: 2024-07-25

Lead Sponsor: Emory University

Target Recruit Count: 36

Registration Number: NCT01489813

Locations: 🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory University Department of Urology, Atlanta, Georgia, United States

A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Ganetespib
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2011-12-06

Last Posted Date: 2015-10-12

Lead Sponsor: Emory University

Target Recruit Count: 8

Registration Number: NCT01485835

Locations: 🇺🇸
The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States
🇺🇸
Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States
🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States

and more 5 locations

Cortisol Suppression and Startle Responses in Posttraumatic Stress Disorder (PTSD)

Not Applicable

Completed

Conditions: Post Traumatic Stress Disorder

Interventions: Drug: Dexamethasone
Drug: Placebo

First Posted Date: 2011-11-23

Last Posted Date: 2017-04-18

Lead Sponsor: Emory University

Target Recruit Count: 165

Registration Number: NCT01477762

Locations: 🇺🇸
Grady Health System, Atlanta, Georgia, United States

A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies

Phase 1

Completed

Conditions: Lung Cancer
Solid Tumors

Interventions: Drug: BKM120
Drug: Everolimus

First Posted Date: 2011-11-11

Last Posted Date: 2018-03-19

Lead Sponsor: Emory University

Target Recruit Count: 43

Registration Number: NCT01470209

Locations: 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

Study of Arsenic Trioxide in Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer
Cancer of Lung
Pulmonary Cancer
Pulmonary Neoplasms
Carcinoma, Small Cell

Interventions: Drug: Arsenic Trioxide

First Posted Date: 2011-11-11

Last Posted Date: 2021-02-17

Lead Sponsor: Emory University

Target Recruit Count: 20

Registration Number: NCT01470248

Locations: 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States

Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases

Phase 1

Completed

Conditions: Neuroendocrine Tumors

Interventions: Drug: Pasireotide
Procedure: Sir-sphere Radioembolization
Drug: Everolimus

First Posted Date: 2011-11-10

Last Posted Date: 2018-10-18

Lead Sponsor: Emory University

Target Recruit Count: 13

Registration Number: NCT01469572

Locations: 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States

Decision-Making in Bipolar Disorder

Not Applicable

Completed

Conditions: Bipolar Disorder

Interventions: Drug: Lithium
Drug: Valproate
Drug: Lamotrigine

First Posted Date: 2011-11-01

Last Posted Date: 2017-05-31

Lead Sponsor: Emory University

Target Recruit Count: 37

Registration Number: NCT01463111

Locations: 🇺🇸
Emory University Mood and Anxiety Disorders Program, Atlanta, Georgia, United States

Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer

Phase 1

Completed

Conditions: Neoplasms, Pancreatic
Pancreas Cancer
Pancreas Neoplasms
Cancer of the Pancreas
Cancer of Pancreas

Interventions: Drug: Modified FOLFIRINOX
Radiation: Stereotactic Body Radiotherapy (SBRT)

First Posted Date: 2011-10-05

Last Posted Date: 2016-03-22

Lead Sponsor: Emory University

Target Recruit Count: 13

Registration Number: NCT01446458

Locations: 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States

Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme

Phase 1

Completed

Conditions: Glioblastoma Multiforme

Interventions: Drug: Temozolomide, bevacizumab and bortezomib

First Posted Date: 2011-09-16

Last Posted Date: 2016-04-27

Lead Sponsor: Emory University

Target Recruit Count: 12

Registration Number: NCT01435395

Locations: 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States

Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin

Phase 1

Terminated

Conditions: Cholangiocarcinoma
Pancreatic Neoplasms

Interventions: Drug: Gemcitabine with TheraSphere

First Posted Date: 2011-09-15

Last Posted Date: 2015-05-04

Lead Sponsor: Emory University

Target Recruit Count: 9

Registration Number: NCT01434459

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy